Victory Capital Management Inc. Has $2.24 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Victory Capital Management Inc. lessened its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 16.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 201,306 shares of the biopharmaceutical company’s stock after selling 38,718 shares during the period. Victory Capital Management Inc. owned 0.15% of Dynavax Technologies worth $2,243,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC raised its position in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the last quarter. US Bancorp DE increased its stake in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP bought a new position in shares of Dynavax Technologies during the third quarter worth about $45,000. Nisa Investment Advisors LLC lifted its stake in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the period. Finally, Algert Global LLC bought a new stake in Dynavax Technologies in the second quarter valued at approximately $140,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

DVAX opened at $12.42 on Monday. The firm has a 50-day moving average price of $11.50 and a 200-day moving average price of $11.32. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of 95.55 and a beta of 1.34. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $15.01. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DVAX. HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.